The Unyvero A50 System is capable of supporting a wide variety of applications for treating severe infectious diseases. Currently there are 5 comprehensive panels for Hospitalized Pneumonia, Implant & Tissue, Intra-Abdominal, Blood Culture and Urinary Tract Infections. With many more applications planned on the horizon, the Unyvero A50 fits perfectly into the care-continuum for modern healthcare organizations.
Hospitalized pneumonia is one of the biggest healthcare problems with mortality rates as high as 30% for high risk patients, and increased ICU stays from 7 to 9 days.+
The rise in antibiotic resistance is only making matters worse. Rapid detection and targeted treatment are key to combating this growing global health issue.
The Unyvero Hospitalized Pneumonia (HPN) Cartridge analyzes a total of 48 genetic markers from sample-to-answer in 4-5 hours, enabling targeted syndromic treatment in the first few critical hours of infection.
The Unyvero HPN Cartridge can be used to diagnose:
- Hospitalized community-acquired pneumonia (hCAP)
- Hospital-acquired (or nosocomial) pneumonia (HAP)
- Ventilator-associated pneumonia (VAP)
- Healthcare-associated pneumonia (HCAP)
- Severe community-acquired pneumonia (SCAP)
Implant and Tissue Infection
Implant and tissue infections can be complex and time-consuming to diagnose. The treatment of patients with implant and tissue infections can only be optimized after microorganisms and associated resistances are known.
The Unyvero Implant & Tissue Infection (ITI) Cartridge tests for 102 pathogens including subspecies and resistance genes. It delivers results with high sensitivity and specificity within just 4-5 hours. With this test panel, physicians can quickly diagnose infections and determine the optimum treatment in a matter of hours.
The Unyvero ITI Cartridge can be used to diagnose:
- Burn wound infections
- Cardiology-associated infections
- Catheter-associated infections
- Deep skin and tissue infections
- Diabetic foot infections
- Orthopedic implant infections
- Implant Infections
- Surgical site infections
Worldwide, every 3 to 4 seconds a person succumbs to sepsis.1 Sepsis continues to rise every year, and mortality rates are as high as 50%.2,3 In industrialized countries, sepsis is already responsible for as many deaths as heart attacks. 4
The Unyvero Blood Culture (BCU) Cartridge for positive blood cultures analyzes 103 DNA analytes from a single sample. It delivers microorganism and antibiotic resistance results with high sensitivity and specificity within just 4-5 hours.
1WSD Fact Sheet 2018 (www.world-sepsis-day.org)
2Hotchkiss RS et al., Sepsis and septic shock. Nat Rev Dis Primers. 2016; 2:16045
3Fleischmann C et al., Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016; 193(3):259-72
4 Institut Pasteur, Disease Sheet -Sepsis, 2014
Intra-abdominal infections are the second most common cause of sepsis identified in intensive care units.1,2 IAI is often associated with a poor prognosis, particularly in high-risk patients. With increasing rates of antibiotic resistance, the clinical picture can deteriorate rapidly. Early clinical diagnosis and appropriate antimicrobial therapy are essential in the management of intra-abdominal infections.3
The Unyvero Intra-Abdominal Infection (IAI) Cartridge analyzes 130 pathogens including subspecies as well as toxins and resistance genes with a sample-to-answer time of 4-5 hours. Based on this comprehensive analysis, physicians can quickly decide on the most appropriate treatment path, which improves outcomes, reduces length of inpatient stays, and lastly lowers healthcare costs.
1Lopez N et al., A Comprehensive review of abdominal infections. World J Emerg Surg. 2011; 6:7
2Sartelli M et al., Current concept of abdominal sepsis: WSES position paper. World J Emerg Surg. 2014; 9:22
3Sartelli M et al., Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World J Emerg Surg. 2017; 12:22
Urinary Tract Infection
Complicated urinary tract infections are among the most prevalent hospital-acquired infections, and are the second most common cause of bacteremia in hospitalized patients.1 The number of urinary tract infections caused by antibiotic-resistant bacteria is increasing.2
As with other serious infections, the key for effective treatment is the early diagnosis of pathogens and associated resistance markers. This allows targeted treatment, better use of available antibiotics, decreased length of hospital stays, and lower healthcare costs.
The Unyvero Urinary Tract Infection (UTI) Cartridge addresses this unmet clinical need with a broad panel of 103 microorganisms and resistance genes. In 4-5 hours, physicians can optimize treatment for their patients with severe UTIs.